Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FEIBA NF prophylaxis versus on-demand in hemophilia A or B with high-titer inhibitors
2008-003855-65Phase 3Completed
- Sponsor
- Baxter International Inc.
- Start
- Jun 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of anti-inhibitor coagulant complex in hemophilia A and hemophilia B (HB) (2 arms), sponsored by Baxter International Inc. Primary endpoint: Primary endpoint: annualized bleed rate reduction. Started Jun 2009; status: completed.
02
Drugs
anti-inhibitor coagulant complex
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on 2008-003855-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003855-65.